The reverse split is a defensive measure to regain Nasdaq compliance, not a fundamental improvement. Monitor whether the stock price holds above the $1 minimum bid threshold in the weeks following the split; failure to maintain compliance could lead to delisting. The company's biopharmaceutical development pipeline and cash runway remain the key drivers of intrinsic value.
Price Chart
Executive Summary
CDT Equity Inc. filed a certificate of amendment to effect a 1-for-25 reverse stock split of its common stock, effective September 28, 2026, to maintain compliance with the Nasdaq minimum bid price rule. Post-split, outstanding shares will be reduced to approximately 1,124,515, and the stock will begin trading on a split-adjusted basis on September 29, 2026, under the same ticker (CDT). The reverse split is a mechanical corporate action with no fundamental change in business operations, but it signals the company was at risk of delisting due to a low stock price.
Key Facts
- 1-for-25 reverse stock split effective September 28, 2026 at 5:00 PM ET; split-adjusted trading begins September 29, 2026.
- Post-split outstanding shares reduced to approximately 1,124,515 shares.
- Reverse split explicitly stated to ensure continued compliance with the Nasdaq bid-price rule.
- No fractional shares issued; cash in lieu paid based on closing price on September 28, 2026.
- Authorized share count remains unchanged at 250,000,000 shares of common stock.
- CUSIP number changes to 20678X700 post-split.
Financial Impact
Reverse stock split reduces share count from approximately 28.1 million to ~1.12 million shares, mechanically increasing per-share price by 25x. No change in market capitalization or enterprise value.
Risk Factors
- Post-split stock price may decline toward the $1 minimum, risking renewed delisting risk.
- Reduced share count reduction may increase volatility and potential for higher short-term price swings.
- No change in underlying business fundamentals; the company remains a pre-revenue biopharma development-stage firm with no approved products.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-044248 |
| Exhibit: ex3-1.htm | 0001493152-26-044248 |
| Exhibit: ex99-1.htm | 0001493152-26-044248 |
| Document: 0001493152-26-044248-index-headers.html | 0001493152-26-044248 |
| Document: 0001493152-26-044248-index.html | 0001493152-26-044248 |
| Document: 0001493152-26-044248.txt | 0001493152-26-044248 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $0.0837 | awaiting T+20 | awaiting T+20 | $0.0800 (−4.42%) |
Oct 27, 2026 today | DEF 14A | $0.0890 | awaiting T+20 | awaiting T+20 | $0.0800 (+10.11%) |
Oct 27, 2026 today | SC 13D/A | $0.0890 | awaiting T+20 | awaiting T+20 | $0.0800 (−10.11%) |
Oct 27, 2026 today | 3 | $0.0819 | awaiting T+20 | awaiting T+20 | $0.0800 (−2.32%) |
Oct 27, 2026 today | 8-K | $0.0982 | awaiting T+20 | awaiting T+20 | $0.0800 (+18.53%) |
Oct 13, 2026 14d ago | 8-K | $0.4500 | awaiting T+20 | awaiting T+20 | $0.0800 (+82.22%) |
Oct 8, 2026 19d ago | SC 13G/A | $0.7180 | awaiting T+20 | awaiting T+20 | $0.0800 (+88.86%) |
Oct 7, 2026 20d ago | SC 13G | $0.8000 | awaiting T+20 | awaiting T+20 | $0.0800 (−90.00%) |
Oct 7, 2026 20d ago | SC 13G/A | $0.8000 | awaiting T+20 | awaiting T+20 | $0.0800 (+90.00%) |
Oct 7, 2026 20d ago | SC 13G/A | $0.8000 | awaiting T+20 | awaiting T+20 | $0.0800 (+90.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers